Remove 2009 Remove Communication Remove Drug Development
article thumbnail

Frontiers Health Steering Committee spotlight – Paul Tunnah

pharmaphorum

Asked how he made the shift from working out the structure of proteins and how molecules bind to those proteins, to the founding of pharmaphorum and focusing on the digital space, his answer was clear: communication. Tunnah realised, in fact, that that communicative passion lay within himself and wasn’t satisfied by academic work.

article thumbnail

FDA sketches a path for patient-focused drug development

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has released the fourth and final chapter in a series of guidance documents designed to support patient-focused drug development. The draft guidance, released on March 5, is open for comments until May 7, after which it will replace an earlier 2009 guidance for the industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

In 2001 and 2007, through 2009, the economy was hit hard. There was a significant slowdown in drug development, clinical trials, and new drugs coming to market. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.

article thumbnail

NHC Comments on PFDD: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making

Putting Patients First Blog

MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. The NHC was a strong supporter of the inclusion of these guidances in the Prescription Drug User Fee Act (PDUFA) VI agreement. Califf M.D., Califf M.D.,

article thumbnail

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

pharmaphorum

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID.

Hospitals 111
article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. GlobalData is the parent company of Pharmaceutical Technology.

article thumbnail

Quality first: How pharma can meet injectables demand while staying compliant

Pharmaceutical Technology

Several drug development trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. FirstLine was developed with a zero-defect philosophy,” explains Santambrogio. This was higher than the number of approvals in 2019 and 2020.